Total Payments
$517.30
2024 Payments
$273.55
Companies
17
Transactions
24
Medicare Patients
3,355
Medicare Billing
$668,137
Payment Breakdown by Category
Food & Beverage$456.80 (88.3%)
Education$60.50 (11.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $456.80 | 20 | 88.3% |
| Education | $60.50 | 4 | 11.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $85.95 | 1 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $75.15 | 3 | $0 (2024) |
| PFIZER INC. | $71.70 | 4 | $0 (2024) |
| Celgene Corporation | $33.90 | 2 | $0 (2024) |
| Merck Sharp & Dohme LLC | $25.61 | 1 | $0 (2024) |
| Genentech USA, Inc. | $24.93 | 2 | $0 (2018) |
| G1 Therapeutics, Inc. | $22.87 | 1 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $22.28 | 1 | $0 (2018) |
| Janssen Biotech, Inc. | $21.45 | 1 | $0 (2020) |
| Incyte Corporation | $18.87 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $273.55 | 13 | Novartis Pharmaceuticals Corporation ($75.15) |
| 2022 | $38.37 | 2 | G1 Therapeutics, Inc. ($22.87) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $21.45 | 1 | Janssen Biotech, Inc. ($21.45) |
| 2018 | $63.55 | 4 | AstraZeneca Pharmaceuticals LP ($22.28) |
| 2017 | $108.46 | 3 | E.R. Squibb & Sons, L.L.C. ($85.95) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: Oncology | ||||||
| 06/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: Oncology | ||||||
| 05/24/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $22.02 | General |
| Category: Hematology | ||||||
| 04/19/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: ONCOLOGY | ||||||
| 04/12/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: ONCOLOGY | ||||||
| 03/23/2024 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: ONCOLOGY | ||||||
| 03/16/2024 | Incyte Corporation | MONJUVI (Drug), JAKAFI, PEMAZYRE | Food and Beverage | Cash or cash equivalent | $18.87 | General |
| Category: Oncology | ||||||
| 03/09/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $28.52 | General |
| Category: ONCOLOGY | ||||||
| 03/01/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), PIQRAY | Food and Beverage | In-kind items and services | $32.51 | General |
| Category: Oncology | ||||||
| 02/12/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: HEMATOLOGY | ||||||
| 02/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), REBLOZYL, WELIREG | Food and Beverage | In-kind items and services | $25.61 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $18.39 | General |
| 01/31/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $14.92 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2022 | PFIZER INC. | LORBRENA (Drug) | Education | In-kind items and services | $15.50 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2022 | G1 Therapeutics, Inc. | COSELA (Drug) | Food and Beverage | Cash or cash equivalent | $22.87 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 01/31/2020 | Janssen Biotech, Inc. | DARZALEX (Drug) | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: Oncology | ||||||
| 10/09/2018 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: BioOncology | ||||||
| 04/03/2018 | AstraZeneca Pharmaceuticals LP | — | Education | In-kind items and services | $22.28 | General |
| 03/07/2018 | PFIZER INC. | BAVENCIO (Drug) | Education | In-kind items and services | $10.80 | General |
| Category: ONCOLOGY | ||||||
| 02/22/2018 | Amgen Inc. | Nplate (Biological), Prolia, XGEVA | Food and Beverage | In-kind items and services | $16.17 | General |
| Category: Hematology | ||||||
| 05/03/2017 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $85.95 | General |
| Category: Oncology | ||||||
| 04/18/2017 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $10.63 | General |
| Category: BioOncology | ||||||
| 03/07/2017 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $11.88 | General |
| Category: Hematology / Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 597 | 1,167 | $212,290 | $121,908 |
| 2022 | 11 | 922 | 1,951 | $332,445 | $200,090 |
| 2021 | 11 | 778 | 1,702 | $275,089 | $173,434 |
| 2020 | 16 | 1,058 | 2,089 | $329,946 | $172,705 |
Total Patients
3,355
Total Services
6,909
Medicare Billing
$668,137
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 148 | 485 | $93,605 | $61,657 | 65.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 318 | 515 | $84,975 | $42,702 | 50.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 55 | $8,030 | $4,883 | 60.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 31 | 37 | $9,768 | $4,766 | 48.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 29 | 29 | $8,004 | $4,070 | 50.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $5,668 | $2,807 | 49.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 20 | $2,240 | $1,023 | 45.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 250 | 852 | $164,436 | $110,955 | 67.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 338 | 576 | $95,040 | $51,169 | 53.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 57 | 62 | $16,368 | $9,036 | 55.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 55 | 55 | $15,180 | $8,422 | 55.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 61 | 61 | $13,298 | $7,179 | 54.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 47 | 93 | $13,578 | $7,010 | 51.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 26 | 29 | $5,829 | $2,516 | 43.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 28 | $2,856 | $1,505 | 52.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 21 | $2,352 | $1,287 | 54.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 25 | 88 | $2,992 | $899.78 | 30.1% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2022 | 25 | 86 | $516.00 | $112.03 | 21.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 267 | 850 | $164,050 | $113,705 | 69.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 260 | 392 | $64,680 | $35,600 | 55.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 36 | 36 | $9,936 | $5,629 | 56.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 33 | 65 | $9,490 | $5,035 | 53.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 25 | 25 | $6,600 | $3,580 | 54.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 24 | 25 | $5,025 | $2,568 | 51.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 20 | 20 | $4,360 | $2,411 | 55.3% |
About Dr. Mark Pajeau, MD
Dr. Mark Pajeau, MD is a Hematology & Oncology healthcare provider based in Rolla, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2007. The National Provider Identifier (NPI) number assigned to this provider is 1114131711.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Pajeau, MD has received a total of $517.30 in payments from pharmaceutical and medical device companies, with $273.55 received in 2024. These payments were reported across 24 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($456.80).
As a Medicare-enrolled provider, Pajeau has provided services to 3,355 Medicare beneficiaries, totaling 6,909 services with total Medicare billing of $668,137. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Rolla, MO
- Active Since 05/10/2007
- Last Updated 07/03/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1114131711
Products in Payments
- EMPLICITI (Biological) $85.95
- KISQALI (Drug) $75.15
- IBRANCE (Drug) $28.52
- KEYTRUDA (Biological) $25.61
- TECENTRIQ (Biological) $24.93
- COSELA (Drug) $22.87
- REBLOZYL (Biological) $22.02
- DARZALEX (Drug) $21.45
- MONJUVI (Drug) $18.87
- LIBTAYO (Biological) $18.54
- MONOFERRIC (Drug) $17.39
- BELEODAQ (Drug) $17.26
- INLYTA (Drug) $16.88
- Nplate (Biological) $16.17
- LORBRENA (Drug) $15.50
- clonoSEQ (Device) $14.92
- Revlimid (Drug) $11.88
- BAVENCIO (Drug) $10.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Rolla
Dr. Kan Huang, Md, MD
Hematology & Oncology — Payments: $20,552
Hematology & Oncology $20,552
Gilda Gomez, M.d, M.D
Hematology & Oncology — Payments: $3,418
Hematology & Oncology $3,418
Dr. Yaqoob Ali, M.d, M.D
Hematology & Oncology — Payments: $319.84
Hematology & Oncology $319.84
Joseph Bond, D.o, D.O
Hematology & Oncology — Payments: $86.71
Hematology & Oncology $86.71